Local Delivery of Enoxaparin to Decrease Restenosis After Stenting: Results of Initial Multicenter Trial | Zendy

R. Stefan Kiesz | Zendy; Paweł Buszman | Zendy; Jack L. Martin | Zendy; Ezra Deutsch | Zendy; M. M. Rozek | Zendy; Ewa Gaszewska | Zendy; Marek Rewicki | Zendy; Piotr Seweryniak | Zendy; Maciej Kośmider | Zendy; Michał Tendera | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Local Delivery of Enoxaparin to Decrease Restenosis After Stenting: Results of Initial Multicenter Trial

Author(s) -

R. Stefan Kiesz,

Paweł Buszman,

Jack L. Martin,

Ezra Deutsch,

M. M. Rozek,

Ewa Gaszewska,

Marek Rewicki,

Piotr Seweryniak,

Maciej Kośmider,

Michał Tendera

Publication year - 2001

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/01.cir.103.1.26

Subject(s) - medicine , restenosis , multicenter study , cardiology , coronary stenting , stent , randomized controlled trial

Enoxaparin inhibits smooth muscle cell proliferation in experimental models. Intimal hyperplasia has been found to be the principal cause of restenosis after coronary stent implantation. We sought to determine whether the intramural delivery of enoxaparin before stenting of de novo lesions decreases restenosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research